Pharmacokinetics Evaluation of Nimotuzumab in Combination with Doxorubicin and Cyclophosphamide in Patients with Advanced Breast Cancer

作     者：Leyanis Rodriguez-Vera Eduardo Fernandez-Sanchez Jorge L. Soriano Noide Batista Maite Lima Joaquin Gonzalez Robin Garcia Carmen Viada Concepcion Peraire Helena Colom Mayra Ramos-Suzarte 

作者机构：Laboratory of Pharmacokinetic Department of Pharmacology & Toxicology Institute of Pharmacy & Foods 222 St. and 23 Avenue La Coronela La Lisa University of Havana Havana CP 13600 Cuba Center for Research and Biological Evaluation Institute of Pharmacy & Foods 222 St. and 23 Avenue La Coronela La LisaUniversity of Havana Havana CP 13600 Cuba Hermanos Ameijeiras Hospital San L6zaro Avenue and Street Belascoain Havana Center Havana Cuba Center of Molecular Immunology Street 216 and 15 Atabey Playa Havana Cuba Pharmacy and Pharmaceutical Technology Department School of Pharmacy University of Barcelona Barcelona Spain 

出 版 物：《Journal of Life Sciences》 (生命科学（英文版）)

年 卷 期：2013年第7卷第11期

页      面：1123-1133页

学科分类：090603[农学-临床兽医学] 090602[农学-预防兽医学] 09[农学] 0906[农学-兽医学] 

主　　题：Breast cancer epidermal growth factor receptor monoclonal antibody nimotuzumab pharmacokinetics 

摘      要：EGFr （Epidermal growth factor receptor） overexpression has been detected in many tumors of epithelial origin, specifically in breast cancer and it is often associated with tumor growth advantages and poor prognosis. The nimotuzumab is a genetically engineered humanized MAb （monoclonal antibody） that recognizes an epitope located in the extracellular domain of human EGFr. The aim of this study was to assess the pharmacokinetics of nimotuzumab in patients with locally advanced breast cancer who are receiving neoadyuvant therapy combined with the AC chemotherapy regimen （i.e., 60 mg/m2 of Doxorubicin and 600 mg/m2 of Cyclophosphamide in 4 cycles every 21 days）. A single center, non-controlled, open Phase I clinical trial, with histopathological diagnosis of locally advanced stage III breast cancer, was conducted in 12 female patients. Three patients were enrolled at each of the following fixed dose levels： 50, 100, 200 and 400 mg/week. Multiple intermittent short-term intravenous infusions of nimotuzumab were administered weekly, except on weeks 1 and 10, when blood samples were drawn for pharmacokinetic assessments. Nimotuzumab showed dose-dependent kinetics. No anti-idiotypic response against nimotuzumab was detected in blood samples of participants. There was not interaction between the administration of nimotuzumab and chemotherapy at the dose levels studied. The optimal biological doses ranging were estimated to be 200 mg/weekly to 400 mg/weekly.